Syngene sets up microbial facility as it expands biopharma-manufacturing capacity

It strengthens Syngene’s portfolio as a fully integrated custom biomanufacturer with added mammalian and microbial capabilities for clinical and commercial supplies

Syngene Q1 FY22 revenue grows 41%

The first quarter performance reflects growth across all its business divisions as the company continued to operate at normal levels

Syngene Q3 revenue up 13% to Rs. 585 Cr

EBITDA and PAT for the quarter were both up 11% to Rs. 193 crores and Rs. 102 crores respectively.

Biocon posts Q4 FY24 PAT at Rs. 135 Cr

EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%

Biocon names Peter Bains as Group CEO

Bains has stepped down from his role on the Biocon Board as an Independent Director with immediate effect

Biocon Q3 FY23 revenue up 36%

The company's consolidated revenues for the quarter grew 36% to Rs. 3,020 crore on the back of robust performance across all its three businesses

Peter Bains appointed Additional Director of Biocon

He has global experience in strategic and operational leadership including at Board, CEO and Senior Corporate levels

Biocon Q2FY23 net profit slips 10% to Rs 168 Cr; Revenue up 26%

Future Packaging to redefine India Pharm industry growth: InnoPack Pharma

The Innopack confex is a perfect platform for exhibitors to demonstrate their latest developments in the fields of pharmaceutical packaging, labelling, drug delivery device design and engineering.

Biocon consolidated PAT at Rs 187.1 cr. in Q3FY22

Biocon has reported consolidated financial results for the period ended December 31, 2021